Positive Outlook for Maze Therapeutics: Promising Pipeline and Strong Financial Position Justify Buy Rating

Leerink Partners analyst Joseph Schwartz has maintained their bullish stance on MAZE stock, giving a Buy rating yesterday.

Joseph Schwartz’s rating is based on Maze Therapeutics’ promising pipeline and solid financial position. The company is advancing its lead asset, MZE829, which targets APOL1 kidney disease and has shown potential to outperform other inhibitors in its class. The differentiation of MZE829, through its design to mimic a protective variant of the APOL1 gene, underscores its innovative approach and potential efficacy.
Additionally, Maze’s second program, MZE782, is progressing well with initial data anticipated in the second half of 2025. The company’s strong cash position, bolstered by $196.8 million in cash and cash equivalents and $140 million from a recent IPO, ensures financial stability to support operations into the second half of 2027. These factors contribute to a positive outlook for Maze Therapeutics, justifying the Buy rating with a price target of $28.